Using Human Menstrual Blood Cells to Treat Acute Lung Injury Caused by H7N9 Bird Flu Virus Infection

S-Evans Biosciences

Status and phase: Unknown; Phase 2; Phase 1

Conditions: Multiple Organ Failure; Acute Respiratory Distress Syndrome (ARDS); Acute Lung Injury

Treatments: Drug: Menstrual blood stem cells

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT02095444

SEB-2014-2-20

Details and patient eligibility

About

The purpose of this study is to determine whether human menstrual blood-derived stem cells are effective in the treatment of infection of H7N9 virus caused acute lung injury.

Full description

1. recruiting volunteers of H7N9 infection: age > 18; patients signed with the informed consent; APACHE II > 20 score
2. patients infused with menstrual blood progenitor cells infusion dose: 1~10×10*7 cells/kg infusion frequency: 2 times a week, 2 weeks for infusion
3. test items and standard spirits lifted; pulmonary function improved; lung image injury improved

Enrollment: 20 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of H7N9 infection
• must be critical injured for lung tissues

Exclusion criteria

• cancer diseases
• pregnancy
• mental disorder
• allergic constitution
• severe inflammation

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 1 patient group

Menstrual blood stem cells

Experimental group

Description:

1x10\*7 cells/kg, IV(in the vein) twice a week. Number of course for two weeks.

Treatment:

Drug: Menstrual blood stem cells